Background Neurofibromatosis type 2 (NF2)-related schwannomatosis is a rare genetic disorder associated with meningiomas. Stereotactic radiosurgery (SRS) has emerged as a potential non-invasive method. This study aims to synthesize the available evidence on using SRS to treat these tumors. Methods PubMed/Medline, Embase, Scopus, and Web of Science were searched until March 21, 2024. This study was prepared by adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Results Four studies were included comprising 101 patients with NF2-associated meningiomas treated with SRS. All included studies used gamma knife stereotactic radiosurgery (GKRS) as treatment modality. Overall survival rates remained high (100%) up to 3 years post-treatment, with slight declines at five years of 98% (95% CI: 0.95–1.01) and ten years of 68% (95% CI: 0.48–0.87). Progression-free survival rates were similarly favorable, with 95% (95% CI: 89-101%) at three years, 93% (95% CI: 86-99%) at five years, and 81% (95% CI: 51-111%) at ten years. The pooled radiation necrosis rate was 5% (95% CI: 3-7%), while the overall radiation toxicity rate was 16% (95% CI: 11-21%). Local tumor control rates were high at six months, and at 12 months, they were 100% (95% CI: 1.00–1.00). Conclusion GKRS demonstrates high efficacy and a favorable safety profile for NF2-associated meningiomas, offering a valuable treatment option for this challenging patient population.
Background Brain metastases (BMs) are a common and fatal consequence in patients with advanced malignancies. Mutations happening in the epidermal growth factor receptor (EGFR) are associated with an elevated risk BMs, occurring in approximately 20–40% of patients. This study evaluates the safety and efficacy of different radiotherapy (RT) modalities in patients with EGFR-mutant lung cancer brain metastases. Method This study was conducted according to the PRISMA guideline. A comprehensive search was conducted on PubMed, Embase, Web of Science, and Scopus, until 13 March 2024. Stata v.17 was used for statistical analysis. Result A total of 57 studies involving 4614 patients were analyzed, with a female predominance of 59.55% and a mean age of 50–70 years. The 6-month overall survival (OS) rate was 94% [95% CI 91–96%], 81% [95% CI 78– 84%] at 1-year, 55% [95% CI 50–60%] at 2-year, 37% [95% CI 32–42%] at 3-year, decreasing to 21% [95% CI 16–26%] at 5 years. Progression-free survival (PFS) rates were 84% [95% CI 79–89%] at 6 months and 20% [95% CI 14–26%] at 3 years. Meta-regression analysis indicated that a higher number of metastases, Karnofsky performance status below 80, and an ECOG score over one were significantly linked to OS outcomes. Conclusion RT significantly improves survival outcomes in patients with EGFR-mutant brain metastases. However, the combination of RT with targeted therapies, such as tyrosine kinase inhibitors (TKIs), appears to offer more favorable outcomes.